Program
IBI3016
A development code. Also written as “IBI3016 Dose 4”, “IBI3016 Dose 3” and “IBI3016 Dose 2”.
Its studies are mostly in Hypertension, led by Innovent Biologics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 33 open or running | phase 2since Jan 13, 2026 | Jan 13, 2026 | Jan 30, 2027phase 1 · NCT07838220 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2026First study: phase 2 study in HypertensionFirst studyNCT07352969 · 352 enrolled · China
- Apr 14, 2026Phase 1 study in HypertensionNCT07556796 · 30 enrolled · China
- Sep 13, 2026Phase 1 study in HypertensionNCT07838220 · 30 planned · Japan
Ahead
- Jan 30, 2027Primary completion: phase 1 study in HypertensionNCT07838220
- Oct 16, 2027Primary completion: phase 1 study in HypertensionNCT07556796
- Mar 27, 2029Primary completion: phase 2 study in HypertensionNCT07352969
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07838220Hypertension · Japan | 1 | Recruiting | Jan 30, 2027 | 30 |
| NCT07556796Hypertension · China | 1 | Active, not recruiting | Oct 16, 2027 | 30 |
| NCT07352969Hypertension · China | 2 | Active, not recruiting | Mar 27, 2029 | 352 |
How it is read
Names in the registry
- “IBI3016”, 2 entries
- “IBI3016 Dose 4”, 1 entry
- “IBI3016 Dose 3”, 1 entry
- “IBI3016 Dose 2”, 1 entry
- “IBI3016 Dose 1”, 1 entry
Codes read as this program: IBI3016.
Conditions, from the studies’ own filings
- Hypertension, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.